Dossier
M42
Coverage of M42 in the Nexus archive.
- Mubadala-backed M42 pitches genomics capabilities to the world
M42, an Abu Dhabi healthcare company backed by Mubadala, is pitching its genomic sequencing capabilities to governments and pharmaceutical companies worldwide. The firm has sequenced nearly 1 million genetic samples and is launching AI chatbots for chronic disease management, starting with kidney.com. M42 plans to expand its data-driven healthcare model globally and develop additional condition-specific platforms.